Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · IEX Real-Time Price · USD
2.020
+0.020 (1.00%)
At close: Jul 19, 2024, 4:00 PM
1.980
-0.040 (-1.98%)
Pre-market: Jul 22, 2024, 7:28 AM EDT
Company Description
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases.
The company’s products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 7, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 384 |
| CEO | Joshua B. Cohen |
Contact Details
Address: 43 Thorndike Street Cambridge, Massachusetts 02141 United States | |
| Phone | 617-683-0917 |
| Website | amylyx.com |
Stock Details
| Ticker Symbol | AMLX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001658551 |
| CUSIP Number | 03237H101 |
| ISIN Number | US03237H1014 |
| Employer ID | 46-4600503 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Justin B. Klee | Co-Founder, Co-Chief Executive Officer and Director |
| Joshua B. Cohen | Co-Founder, Co-Chief Executive Officer and Director |
| James M. Frates M.B.A. | Chief Financial Officer |
| Gina M. Mazzariello | Chief Legal Officer and General Counsel |
| Tom Holmes | Chief Technical Operations Officer |
| Lindsey Allen | Head of Investor Relations and Communications |
| Shauna Horvath | Head of Global Marketing |
| Linda A. Arsenault | Chief Human Resources Officer |
| Chris Aiello | Head of Canada and GM |
| Keith White | Head of Global Market Access |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 10, 2024 | 8-K | Current Report |
| Jul 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jun 21, 2024 | 8-K | Current Report |
| Jun 6, 2024 | 8-K | Current Report |
| May 15, 2024 | 144 | Filing |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 24, 2024 | ARS | Filing |
| Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2024 | DEF 14A | Other definitive proxy statements |